natgillin/translations-raw huggingface dataset:
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. 
Ko so izločili bolnike, ki so bili v času diagnoze rak mehurja preiskovanemu zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06%) raka mehurja pri pioglitazonu in 2 primera (0,02%) v kontrolnih skupinah.
The other side effects that have been experienced by some patients when Actos is taken with other antidiabetic medicines are: 
Drugi neželeni učinki, ki so se pojavili pri nekaterih bolnikih, ki so jemali zdravilo Actos skupaj z drugimi antidiabetičnimi zdravili, so:
At two years, glycaemic control (defined as HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. 
Po dveh letih je nadzor glikemije (definiran kot HbA1c < 8,0%) vztrajal pri 69% bolnikov, zdravljenih s pioglitazonom, v primerjavi s 50% bolnikov, ki so prejemali gliklazid.
If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. 
Če ste vzeli večji odmerek zdravila Actos, kot bi smeli Če po nesreči zaužijete preveč tablet ali če kdo drug ali otrok zaužije vaša zdravila, o tem nemudoma obvestite svojega zdravnika ali farmacevta.
If ALT levels are increased to 3 x upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. 
Če se med zdravljenjem s pioglitazonom ravni ALT zvišajo do 3-kratne zgornje meje normalnih vrednosti, je treba ravni jetrnih encimov čim prej ponovno kontrolirati.
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
2 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri drugih hipoglikemičnih učinkovinah.
If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible. 
V primeru pojava resne alergijske reakcije, ki vključuje koprivnico in otekanje obraza, ustnic, jezika ali žrela, kar lahko povzroči težave z dihanjem ali s požiranjem, takoj prenehajte z jemanjem tega zdravila in nemudoma poiščite zdravniško pomoč.
- if you are allergic to pioglitazone or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Actos - če ste alergični na pioglitazon ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group. 
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45%, v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini zdravljeni s pioglitazonom.
Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness. 
V vsaki skupini organskih sistemov so neželeni učinki razvrščeni najprej po padajoči pogostnosti in nato po padajoči resnosti.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. 
Izračunana incidenca zlomov je bila 1,9 zlomov na 100 bolniških let pri ženskah, zdravljenih s pioglitazonom in 1,1 zlom na 100 bolnikov-let pri ženskah, zdravljenih s primerjalnim zdravilom.
See section 2 “Actos contains lactose monohydrate”. 
Glejte poglavje 2 “Zdravilo Actos vsebuje laktozo monohidrat”.
Investigations weight increased6 
Preiskave povečanje telesne mase6
− The other ingredients are lactose monohydrate, hyprolose, carmellose calcium and magnesium stearate. 
- Pomožne snovi so laktoza monohidrat, hiproloza, kalcijev karmelozat in magnezijev stearat.
The European Medicines Agency has waived the obligation to submit the results of studies with Actos in all subsets of the paediatric population in type 2 diabetes mellitus. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Actos pri vseh podskupinah pediatrične populacije s sladkorno boleznijo tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin 
Kombinacija z metforminom s sulfonilsečnino z metforminom in sulfonilsečnino z insulinom
Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 and 196 tablets. 
Aluminij/aluminij pretisni omoti, pakiranja po 14, 28, 30, 50, 56, 84, 90, 98, 112 in 196 tablet.
The tablets are supplied in blister packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets. 
Tablete so na voljo v pretisnih omotih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali 196 tablet.
Actos contains pioglitazone. 
Zdravilo Actos vsebuje pioglitazon.
common common uncommon macular oedema not known not known not known not known not known 
pogosti pogosti občasni makularni edem neznana neznana neznana neznana neznana
Lilly Hungária Kft. Tel: +36 1 328 5100 
Magyarország Lilly Hungária Kft. Tel: +36 1 328 5100
Steady state pharmacokinetics are similar in patients age 65 and over and young subjects. 
Farmakokinetika v stanju dinamičnega ravnovesja je pri bolnikih, starih 65 let in več, podobna kot pri mlajših osebah.
Hepatic impairment Pioglitazone should not be used in patients with hepatic impairment (see sections 4.3 and 4.4). 
Jetrna okvara Pioglitazona pri bolnikih z jetrno okvaro ne smemo uporabljati (glejte poglavji 4.3 in 4.4).
It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus in adults, when metformin is not suitable or has failed to work adequately. 
Je antidiabetično zdravilo za zdravljenje sladkorne bolezni tipa 2 (od insulina neodvisne sladkorne bolezni) pri odraslih, če zdravljenje z metforminom ni primerno ali ne deluje dovolj dobro.
Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. 
Ker sta tako insulin kot pioglitazon povezana z zastajanjem tekočine, lahko sočasno jemanje poveča tveganje za edeme.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4). 
Pioglitazon je indiciran tudi za kombinacijo z insulinom pri odraslih bolnikih s sladkorno boleznijo tipa 2 z nezadostnim nadzorom glikemije, ki se zdravijo z insulinom, za katere je metformin, zaradi kontraindikacij ali neprenašanja, neprimeren (glejte poglavje 4.4).
In animal fertility studies there was no effect on copulation, impregnation or fertility index. 
V študijah plodnosti pri živalih ni bilo vpliva na parjenje, oploditev ali rodnost.
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
V 3,5 letni PROactive študiji je 44/870 (5,1%) žensk, zdravljenih s pioglitazonom imelo zlome, v primerjavi s 23/905 (2,5%) žensk, zdravljenih s primerjalnim zdravilom.
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite 
pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - glavobol - omotica - bolečine v sklepih - impotenca - bolečine v hrbtu - težko dihanje - majhno znižanje števila rdečih krvnih celic - vetrovi občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - sladkor v urinu, beljakovine v urinu - povišanje vrednosti encimov - občutek vrtenja (vrtoglavica) - znojenje
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. 
Študijo s pioglitazonom, kjer so spremljali kardiovaskularni izid, so opravili pri bolnikih, mlajših od 75 let, s sladkorno boleznijo tipa 2 in že obstoječimi težjimi makrovaskularnimi boleznimi.
Do not use this medicine after the expiry date which is stated on the carton and the blister pack after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
You may take your tablets with or without food. 
Zdravilo Actos skupaj s hrano in pijačo Tablete lahko jemljete skupaj s hrano ali brez nje.
If you experience this symptom for the first time, talk to your doctor as soon as possible. 
Če ste prvič opazili ta simptom, se čim prej posvetujte s svojim zdravnikom.
Musculoskeletal and connective tissue disorders fracture bone4 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva zlomi kosti4
Pioglitazone did not cause statistically significant increases in LDL cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. 
Pioglitazon ni povzročil statistično pomembnih povišanj ravni LDL holesterola v primerjavi s placebom, pri metforminu in gliklazidu pa so opazili znižanja teh vrednosti.
Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ker obstaja možnost povečanja od odmerka odvisnih neželenih učinkov, bo morda ob sočasnem dajanju gemfibrozila treba znižati odmerek pioglitazona.
- hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - cardiac failure or history of cardiac failure (NYHA stages I to IV) - hepatic impairment - diabetic ketoacidosis - current bladder cancer or a history of bladder cancer - uninvestigated macroscopic haematuria 
- s preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 - s srčnim popuščanjem ali srčnim popuščanjem v anamnezi (NYHA razredi od I do IV) - z okvarjenim delovanjem jeter - z diabetično ketoacidozo - z rakom mehurja ali rakom mehurja v anamnezi - z neraziskano makroskopsko hematurijo
How to take Actos 
Kako jemati zdravilo Actos
In vitro studies have shown no inhibition of any subtype of cytochrome P450. 
Študije in vitro niso pokazale inhibicije katerega koli podtipa citokroma P450.
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
kot trojno peroralno zdravljenje v kombinaciji: - z metforminom in s sulfonilsečnino pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub dvojnemu peroralnemu zdravljenju.
Adverse reaction Frequency of adverse reactions of pioglitazone by treatment regimen 
Pogostnost neželenih učinkov pioglitazona glede na režim zdravljenja
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 mL/min) (see section 5.2). 
Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina > 4 ml/min) odmerka ni treba prilagajati (glejte poglavje 5.2).
Post-marketing, bone fractures have been reported in both male and female patients (see section 4.4) 
V obdobju trženja zdravila so poročali o zlomih kosti tako pri bolnikih kot bolnicah (glejte poglavje 4.4).
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3-4% in hematokrit 3,6-4,1% relativna znižanja) in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1-2% in hematokrit 1-3,2% relativna znižanja).
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to< 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
Neželeni učinki, o katerih so poročali večkrat (> 0,5%) kot pri placebu in več kot enkrat pri bolnikih, ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po skupinah organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
V 20-tedenski študiji je pioglitazon znižal raven trigliceridov na tešče, pa tudi hipertrigliceridemijo po obroku prek učinkovanja na absorbirane in v jetrih sintetizirane trigliceride.
Takeda Pharma AS Tel: +372 617 7669 
Eesti Takeda Pharma ASTel: +372 617 7669
The usual starting dose is one tablet of 15 mg or of 30 mg of pioglitazone to be taken once daily. 
Običajni začetni odmerek je ena 15-miligramska ali 30 miligramska tableta pioglitazona enkrat na dan.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Actos and insulin experienced the development of heart failure. 
Pri nekaterih bolnikih z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo se je pri zdravljenju z zdravilom Actos in insulinom pojavilo srčno popuščanje.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. 
Zlome so opazili pri 2,6% žensk, ki so jemale pioglitazon v primerjavi z 1,7% žensk, zdravljenih s primerjalnim zdravilom.
common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia) 
pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - okužba dihal - motnje vida - povečanje telesne mase - odrevenelost občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - vnetje sinusov (sinuzitis) - težave s spanjem (nespečnost)
7 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
7 V kliničnih preskušanjih pioglitazona je bila incidenca povišanih vrednosti ALT, višjih kot trikratna zgornja meja normalnih vrednosti, enaka kot pri placebu, vendar nižja kot v primerjalnih skupinah z metforminom ali sulfonilsečnino.
Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure (see section 4.4). 
O srčnem popuščanju so poročali tudi pri tržni uporabi pioglitazona, in sicer pogosteje pri uporabi pioglitazona v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja (glejte poglavje 4.4).
Your blood sugar will be checked, and your dose of Actos may need to be changed. 
Odmerek zdravila Actos bo morda treba spremeniti.
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
6 V kontroliranih preskušanjih s primerjalnim zdravilom je bilo povprečno povečanje telesne mase pri pioglitazonu, dajanemu kot monoterapija, 2-3 kg v enem letu.
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. 
kot dvojno peroralno zdravljenje v kombinaciji: - z metforminom pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku metformina v monoterapiji - s sulfonilsečnino, le pri odraslih bolnikih, ki ne prenašajo metformina ali je metformin pri njih kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku sulfonilsečnine v monoterapiji.
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. 
Študije in vitro niso dale dokazov, da pioglitazon inhibira kateri koli podtip citokroma P450.
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration. 
Opravljena je bila skupna analiza neželenih učinkov zlomov kosti iz randomiziranih, s primerjalnim zdravilom kontroliranih, dvojno slepih kliničnih preskušanj pri več kot 8.100 bolnikov v skupini, zdravljeni s pioglitazonom in 7.400 v skupini, zdravljeni s primerjalnim zdravilom, ki so trajale do 3,5 let.
Blurred vision due to swelling (or fluid) at the back of the eye has also been reported in patients taking Actos (frequency cannot be estimated from the available data). 
Pri bolnikih, ki so jemali zdravilo Actos, so poročali tudi o zamegljenem vidu zaradi otekanja (ali tekočine) očesnega ozadja (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Each tablet contains 76.34 mg of lactose monohydrate (see section 4.4). 
Pomožne snovi z znanim učinkom Ena tableta vsebuje 76,34 mg laktoze monohidrata (glejte poglavje 4.4).
Each tablet contains 92.87 mg of lactose monohydrate (see section 4.4). 
Pomožne snovi z znanim učinkom Ena tableta vsebuje 92,87 mg laktoze monohidrata (glejte poglavje 4.4).
Metabolism and nutrition disorders hypo-glycaemia uncommon very common common appetite increased uncommon 
Presnovne in prehranske motnje hipoglikemija občasni zelo pogosti pogosti povečan apetit občasni
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
V 3,5 letni PROactive študiji kardiovaskualarnega tveganja, je 44/870 (5,1%; 1,0 zlom na 100 bolnikov-let) žensk, zdravljenih s pioglitazonom imelo zlome, v primerjavi s 23/905 (2,5%;
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Actos. 
Obstaja povečana možnost zanositve, saj se vam pri jemanju zdravila Actos ovulacija lahko povrne.
Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 x upper limit of normal) or with any other evidence of liver disease. 
Pri bolnikih s povišanimi izhodiščnimi ravnmi jetrnih encimov (ALT > 2,5-kratna zgornja meja normalnih vrednosti) ali s kakršnimi koli drugimi znaki jetrne bolezni, zdravljenja s pioglitazonom ne smemo začeti.
Each tablet contains 114.51 mg of lactose monohydrate (see section 4.4). 
Pomožne snovi z znanim učinkom: Ena tableta vsebuje 114,51 mg laktoze monohidrata (glejte poglavje 4.4).
Lilly S.A. Tel: +34 (91) 663 50 00 
Tel: +34 (91) 663 50 00
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. 
Poročali so, da sočasno dajanje pioglitazona z gemfibrozilom (zaviralcem citokroma P450 2C8) povzroči 3-kratno povečanje AUC pioglitazona.
No special requirements for disposal. 
6.6 Posebni varnostni ukrepi za odstranjevanje Ni posebnih zahtev za odstranjevanje.
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Po prihodu zdravila na trg so poročali o primerih srčnega popuščanja, ko so pioglitazon uporabljali v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
- if you retain water (fluid retention) or have heart failure problems, in particular if you are over 75 years old. 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Actos se posvetujte z zdravnikom ali farmacevtom (glejte tudi poglavje 4): - če zadržujete vodo (zastajanje tekočine v telesu) ali imate težave s srčnim popuščanjem, zlasti če ste starejši od 75 let.
Actos contains lactose monohydrate 
Zdravilo Actos vsebuje laktozo monohidrat
The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. 
Morda bo ob sočasnem dajanju rifampicina treba povišati odmerek pioglitazona.
Respiratory, thoracic and mediastinal disorders dyspnoea common 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja pogosti
There was no tumorigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months. 
Hiperplazije sečnega mehurja pri psih ali opicah, ki so prejemali pioglitazon do 12 mesecev, niso opažali.
Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Actos. 
Pri bolnikih, ki so jemali zdravilo Actos, so poročali o alergijskih reakcijah z neznano pogostnostjo (iz razpoložljivih podatkov je ni mogoče oceniti).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 13. oktober 2000
Combination use with insulin should be considered with caution in the elderly because of increased risk of serious heart failure. 
Zaradi povečanega tveganja za hudo srčno odpoved je potrebna previdnost pri kombinirani uporabi z insulinom pri starejših.
common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon alanine aminotransferase increased7 
pogosti pogosti pogosti pogosti pogosti povišana vrednost keratin fosfokinaze v krvi pogosti povišana vrednost laktatne dehidrogenaze občasni povišana vrednost alanin aminotransferaze neznana neznana neznana neznana neznana
Actos may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar. 
Zdravilo Actos se lahko uporablja kot samostojno zdravilo pri bolnikih, ki ne morejo jemati metformina, in ko zdravljenje z dieto in s telesno vadbo ni uspešno pri nadzoru krvnega sladkorja.
common common common common common arthralgia common common common back pain common 
pogosti pogosti pogosti pogosti pogosti artralgija pogosti pogosti pogosti bolečine v hrbtu pogosti
Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon 
Infekcijske in parazitske bolezni okužba zgornjih dihal pogosti pogosti pogosti pogosti pogosti bronhitis pogosti sinuzitis občasni občasni občasni občasni občasni